COVID-19 Vaccine Effectiveness against Omicron Variant among Underage Subjects: The Veneto Region's Experience.

COVID-19 Delta Omicron SARS-CoV-2 VOCs age-group of adolescents age-group of children public health vaccine effectiveness vaccines

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
20 Aug 2022
Historique:
received: 27 07 2022
revised: 13 08 2022
accepted: 17 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Even if most of the complications due to COVID-19 are observed in the elderly, in Italy the impact of COVID-19 among young people has not been negligible. Furthermore, their contribution to SARS-CoV-2 circulation is still unclear. These reasons have driven policy makers to involve subjects aged 5 to 17 years in the COVID-19 vaccination campaign. However, the trade-off of vaccinating this age-group should be further investigated, especially in view of the rise of new immunologically evasive variants of concern (VOCs). We used regional databases to retrospectively estimate vaccine effectiveness over time of each approved vaccination schedule among children (5-11) and adolescents (12-17). Our findings suggest that COVID-19 vaccines were highly effective and their protection levels lasted longer during a period of Delta variant predominance, whereas they offered just mild to moderate levels of protection-apparently affected by a rapid waning effect-in a period of Omicron variant predominance. Considering these results, it is plausible to evaluate a reformulation of possible future COVID-19 vaccination campaigns among underage subjects. However, effectiveness against serious complications due to COVID-19, as well as indirect benefits of underage vaccinations, should first be addressed. Furthermore, vaccine effectiveness should be kept monitored, as new VOCs may arise, but also new adapted vaccines may start being administered.

Identifiants

pubmed: 36016248
pii: vaccines10081362
doi: 10.3390/vaccines10081362
pmc: PMC9413750
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

JAMA Pediatr. 2021 Jun 1;175(6):586-593
pubmed: 33480966
J Formos Med Assoc. 2021 Jun;120 Suppl 1:S95-S105
pubmed: 34108119
Pediatr Clin North Am. 2021 Oct;68(5):1081-1091
pubmed: 34538300
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-428
pubmed: 35298453
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Clin Infect Dis. 2021 Jul 1;73(1):148-150
pubmed: 32761228
Int J Environ Res Public Health. 2022 Jul 04;19(13):
pubmed: 35805837
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018
pubmed: 34982465
Lancet Reg Health Eur. 2022 Aug;19:100429
pubmed: 35821715
Nat Commun. 2022 Jun 9;13(1):3203
pubmed: 35680872
Vaccines (Basel). 2022 Mar 04;10(3):
pubmed: 35335028
Int J Environ Res Public Health. 2022 Mar 23;19(7):
pubmed: 35409513
Front Pediatr. 2021 Aug 10;9:705882
pubmed: 34447727
Nat Med. 2022 May;28(5):1063-1071
pubmed: 35189624
Lancet. 2022 Jul 9;400(10346):97-103
pubmed: 35780801
J Chem Inf Model. 2022 Jan 24;62(2):412-422
pubmed: 34989238
Pediatr Infect Dis J. 2020 Dec;39(12):e388-e392
pubmed: 33031141
N Engl J Med. 2022 May 19;386(20):1899-1909
pubmed: 35353976
JAMA. 2022 Jun 14;327(22):2210-2219
pubmed: 35560036
Front Public Health. 2022 Mar 30;10:842862
pubmed: 35433579
Vaccines (Basel). 2021 Apr 10;9(4):
pubmed: 33920109
Int J Infect Dis. 2021 Feb;103:246-256
pubmed: 33227520
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
PLoS One. 2021 Jun 23;16(6):e0253473
pubmed: 34161376
Vaccines (Basel). 2022 Jan 11;10(1):
pubmed: 35062767
Int J Public Health. 2021 Aug 18;66:1604076
pubmed: 34483809
J Paediatr Child Health. 2022 Jan;58(1):46-53
pubmed: 34694037
Eur Child Adolesc Psychiatry. 2022 Aug;31(8):1-11
pubmed: 33770275
Risk Manag Healthc Policy. 2022 Feb 09;15:219-227
pubmed: 35173498
Lancet Child Adolesc Health. 2021 Oct;5(10):708-718
pubmed: 34358472
Eur J Pediatr. 2021 Jul;180(7):2019-2034
pubmed: 33599835
Microbiol Spectr. 2022 Feb 23;10(1):e0202921
pubmed: 35107327
CMAJ Open. 2022 Apr 12;10(2):E357-E366
pubmed: 35414597
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613

Auteurs

Silvia Cocchio (S)

Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.

Federico Zabeo (F)

Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.

Giulia Tremolada (G)

Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.

Giacomo Facchin (G)

Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.

Giovanni Venturato (G)

Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.

Thomas Marcon (T)

Azienda Zero (Veneto Region), 35100 Padua, Italy.

Mario Saia (M)

Azienda Zero (Veneto Region), 35100 Padua, Italy.

Michele Tonon (M)

Regional Directorate of Prevention, Food Safety, Veterinary, Public Health-Veneto Region, 30123 Venice, Italy.

Michele Mongillo (M)

Regional Directorate of Prevention, Food Safety, Veterinary, Public Health-Veneto Region, 30123 Venice, Italy.

Filippo Da Re (F)

Regional Directorate of Prevention, Food Safety, Veterinary, Public Health-Veneto Region, 30123 Venice, Italy.

Francesca Russo (F)

Regional Directorate of Prevention, Food Safety, Veterinary, Public Health-Veneto Region, 30123 Venice, Italy.

Vincenzo Baldo (V)

Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.

Classifications MeSH